International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma.
Abou-Alfa G, Yen Y, Harding J, Whang-Peng J, Shi Y, Yuen M, Li X, Gu S, Liu C, Jeng L, Yen C, Pan C, Chen S, Hsieh J, Saif M, Liu S, Li F, Lam W, Chu E, Cheng Y. International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16244.Peer-Reviewed Original ResearchProgression-free survivalPer-protocol setPlacebo armYIV-906Child-Pugh A liver functionMulti-targeted tyrosine kinase inhibitorRandomized phase 2 studyTumor rejection in vivoRandomized placebo-controlled studyRisk of disease progressionTumor microenvironment inflammationAdvanced hepatocellular carcinomaECOG performance statusPlacebo-controlled studyPhase 2 studyTyrosine kinase inhibitorsRejection in vivoCohort of patientsPotential clinical benefitCTCAE versionTolerated sorafenibSorafenib monotherapyDouble-blindPlacebo-ControlledITT group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply